Home » Stocks » ALGS

Aligos Therapeutics, Inc. (ALGS)

Stock Price: $27.13 USD 0.05 (0.18%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 1.03B
Revenue (ttm) n/a
Net Income (ttm) -108.54M
Shares Out 35.06M
EPS (ttm) -10.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $27.13
Previous Close $27.08
Change ($) 0.05
Change (%) 0.18%
Day's Open 27.39
Day's Range 26.51 - 27.64
Day's Volume 47,720
52-Week Range 12.82 - 37.51

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SOUTH SAN FRANCISCO, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address u...

1 week ago - GlobeNewsWire

Aligos now evaluating two of its four Chronic Hepatitis B (CHB) portfolio drug candidates in patients Aligos now evaluating two of its four Chronic Hepatitis B (CHB) portfolio drug candidates in patients

3 weeks ago - GlobeNewsWire

- Advanced ALG-010133 and ALG-000184 into the clinic - both expected to generate safety and antiviral activity data in Chronic Hepatitis B (CHB) patients in 2021 - Listed on NASDAQ Global Select Market ...

1 month ago - GlobeNewsWire

The first drug candidate in Aligos's chronic hepatitis B portfolio to be administered to CHB patients The first drug candidate in Aligos's chronic hepatitis B portfolio to be administered to CHB patients

1 month ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address u...

1 month ago - GlobeNewsWire

Aligos (ALGS) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

4 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced that it has entered into an Exclusive License and Research Collaboration Agreement...

5 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address un...

5 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif. and LEUVEN, Belgium, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therap...

5 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address un...

6 months ago - GlobeNewsWire

Nine IPOs and five SPACs went public this past week, and one IPO postponed.

Other stocks mentioned: ARRY, CDAK, EBC, OPT, PRAX, SPEL, TARS
6 months ago - Seeking Alpha

Shares of Aligos Therapeutics Inc. rallied out of the gate Friday, as they opened 16% above the initial public offering price. The stock's first trade on the Nasdaq was at $17.40 at 1:33 p.m.

6 months ago - Market Watch

SOUTH SAN FRANCISCO, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced the pricing of its initial public offering of 10,000,000 shares of its common stoc...

6 months ago - GlobeNewsWire

About ALGS

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a synthetic oligonucleotide that is in Phase I clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company is also developing ALG-020572, an antisense oligonucleotide to decrease HBsAg levels; and ALG-055009, a small molecule THR-ß... [Read more...]

Industry
Biotechnology
IPO Date
Oct 16, 2020
Stock Exchange
NASDAQ
Ticker Symbol
ALGS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for ALGS stock is "Buy." The 12-month stock price forecast is 34.33, which is an increase of 26.54% from the latest price.

Price Target
$34.33
(26.54% upside)
Analyst Consensus: Buy